EJNMMI Research最新文献

{"title":"Cardiometabolic disorders affect myocardial [¹⁸F]fluorodeoxyglucose uptake- impact on diagnostic PET/CT imaging.","authors":"Suvi Hartikainen, Ville Vepsäläinen, Tuomo Tompuri, Tiina M Laitinen, Marja Hedman, Tomi Laitinen","doi":"10.1186/s13550-025-01278-8","DOIUrl":"10.1186/s13550-025-01278-8","url":null,"abstract":"<p><strong>Background: </strong>Corresponding to impaired insulin response in skeletal muscle, insulin resistance may occur in the myocardium, suggesting a link between cardiometabolic disorders and cardiac glucose metabolism. We aimed to investigate whether cardiometabolic disorders predict myocardial [¹⁸F]fluorodeoxyglucose ([¹⁸F]FDG) uptake suppression in cardiac positron emission tomography / computed tomography (PET/CT) following a ketogenic diet and fasting.</p><p><strong>Results: </strong>The study included 100 patients undergoing [¹⁸F]FDG-PET/CT following a ketogenic diet of 1-2 days and a 12 h fast. Blood glucose, insulin, β-hydroxybutyrate (BHB), cholesterol, triglycerides and free fatty acid (FFA) levels were measured before [¹⁸F]FDG injection and later off-diet following overnight fast. The homeostatic model assessment-insulin resistance (HOMA-IR) value was calculated. Non-contrast computed tomography was used to assess the presence of fatty liver and visceral and subcutaneous fat areas. Suppression of myocardial [¹⁸F]FDG uptake was considered adequate if myocardial uptake was equal to or lower than the blood pool background. Compared to inadequate suppression, adequate suppression was associated with higher levels of BHB (median 0.26 mmol/l for inadequate and 0.43 mmol/l for adequate suppression, p = 0.004), FFA (0.58 mmol/l and 0.76 mmol/l respectively, p < 0.001), triglycerides (0.87 mmol/l and 1.12 mmol/l respectively, p = 0.028), and lower liver-spleen attenuation ratios (1.17 and 1.04 respectively, p = 0.013). Low HDL cholesterol, high triglycerides and off-diet HOMA-IR, as well as visceral adiposity, fatty liver and hypertension, predicted adequate suppression in men. Elevated BHB and FFA were significant predictors of adequate suppression in women.</p><p><strong>Conclusions: </strong>Cardiometabolic disorders are associated with lower myocardial [¹⁸F]FDG uptake. Insulin resistance and several other cardiometabolic risk factors are associated with attenuated uptake, especially in men. In women, factors reflecting metabolic response to a ketogenic diet and fasting have a more pronounced effect on myocardial [¹⁸F]FDG uptake.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"80"},"PeriodicalIF":3.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head to head comparison of two PET/CT imaging agents, [¹⁸F]D3FSP ([¹⁸F]P16-129) and [¹⁸F]AV45, in patients with alzheimer's disease.","authors":"David Alexoff, Dean F Wong, Hiroto Kuwabara, Robert F Dannals, Karl Ploessl, Hank F Kung","doi":"10.1186/s13550-025-01276-w","DOIUrl":"10.1186/s13550-025-01276-w","url":null,"abstract":"<p><strong>Background: </strong>A new β-amyloid (Aβ) targeting radiotracer, [¹⁸F]D3FSP ([¹⁸F]P16-129), for diagnosis of Alzheimer's disease (AD) is reported. This radiotracer is a deuterated N-methyl derivative of Amyvid (AV-45, florbetapir f18) which was FDA-approved in 2013. Deuteration may alter a tracer's PK such that imaging performance is improved. A head-to-head comparison between these two imaging agents was conducted in AD patients. A separate biodistribution study was conducted on six healthy subjects, and radiation dosimetry estimation was obtained.</p><p><strong>Results: </strong>Eight patients, clinically diagnosed with Alzheimer's disease, had an average age of 61.1 ± 10.0 years, and an average MMSE score of 21 ± 4. Each patient underwent paired 90-minute dynamic PET/CT scans separately within a few weeks (323 ± 31 MBq of [¹⁸F]D3FSP or [¹⁸F]AV45; florbetapir f18). SUVR (50-70 min) and Distribution Volume Ratio (DVR) of 43 brain regions were evaluated. The average SUVR across cortical gray matter was 1.65 ± 0.21 for [¹⁸F]AV45 and 1.65 ± 0.23 for [¹⁸F]D3FSP, while global DVRs were 1.36 ± 0.14 and 1.37 ± 0.13 for [¹⁸F]AV45 and [¹⁸F]D3FSP respectively. Strong correlations (R² = 0.8-0.9) were observed between tracers for both SUVR and DVR, with slopes of ~ 0.9 (SUVR) and ~ 1 (DVR). No image artifacts or confounds influenced the visual interpretation of [¹⁸F]D3FSP compared to [¹⁸F]AV45.</p><p><strong>Conclusions: </strong>Results showed no difference between [¹⁸F]D3FSP and [¹⁸F]AV45 and no benefit of deuteration at the N-methyl site. Even so, [¹⁸F]D3FSP may be a useful alternative for PET/CT imaging of Aβ deposits in the brain as its binding characteristics were very similar to its non-deuterated analog, the FDA-approved drug [¹⁸F]AV45.</p><p><strong>Trial registration: </strong>Clinicaltrials.org, NCT03902548. Registered 01/07/2018.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"77"},"PeriodicalIF":3.1,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of test-retest reproducibility by [¹⁸F]Bavarostat for PET imaging of HDAC6.","authors":"Mika Naganawa, Ming-Qiang Zheng, Jean-Dominique Gallezot, Robin Bonomi, Jiwei Gu, Hong Gao, Swanee Jacutin-Porte, Nabeel B Nabulsi, Michel Koole, Koen Van Laere, David Matuskey, Yiyun Huang, Richard E Carson","doi":"10.1186/s13550-025-01268-w","DOIUrl":"10.1186/s13550-025-01268-w","url":null,"abstract":"<p><strong>Background: </strong>Histone deacetylase 6 (HDAC6) is an enzyme pivotal for gene regulation, influencing cellular pathways through protein deacetylation. HDAC6 is a potential therapeutic target in diseases such as cancer and neurodegenerative disorders. Koole et al. investigated brain binding of [¹⁸F]Bavarostat, an HDAC6 inhibitor, in healthy participants, revealing an absolute test-retest variability (aTRV) of 7.7% (n = 4) for the distribution volume (V_T) with a 1-day interscan interval. This study aims to evaluate test-retest reproducibility with a more extended interscan interval.</p><p><strong>Results: </strong>Six participants (3 M/3F) underwent a test-retest scan, each lasting for 120 min using a 4-ring Biograph mCT PET/CT scanner. Arterial blood sampling and metabolite analysis were performed to derive the input function. The two scans were 28 ± 12 days apart (14-43 days, n = 6). Regional time-activity curves (TACs) were generated for 15 regions of interest (ROIs). Kinetic analysis of the 120-min TACs was performed using one-tissue and two-tissue compartment models (1TC, 2TC) and multilinear analysis-1 (MA1) to quantify V_T values and compute absolute test-retest variability (aTRV). The effects of scan duration (60 to 120 min) and MA1 t* setting on aTRV and bias were investigated. Careful analysis of the plasma HPLC data was needed since metabolites eluted close in time to the parent. The MA1 model (t* = 40 min) adequately described regional TACs and produced stable kinetic parameters with good agreement to 2TC (MA1 V_T=0.98 × 2TC V_T + 0.48, bias: -0.1%) while 1TC underestimated V_T by 5.1%. Regional V_T values exhibited a relatively uniform pattern, highest in the amygdala and lowest in the centrum semiovale. Individual aTRV values ranged from 2 to 9%. Scan durations between 100 and 120 min provided the most consistent results, with minimal bias and acceptable aTRV across all tested t* values. Although a 90-minute scan with t*=10 or 20-minute balanced scan time and aTRV, optimal parameters varied by brain region. Smaller regions (e.g., amygdala) required longer scans to achieve reliable V_T quantification.</p><p><strong>Conclusions: </strong>The test-retest variability of [¹⁸F]Bavarostat V_T values demonstrated favorable results for a one-month scan interval, comparable to the reported values.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"76"},"PeriodicalIF":3.1,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative renal [^99mTc]DMSA imaging predicts urinary [^99mTc]DMSA excretion in patients with chronic kidney disease.","authors":"Danny Jensen, Jesper Frank Andersen, Peder Berg, Henrik Birn, Christian Flø, Jørgen Frøkiær","doi":"10.1186/s13550-025-01272-0","DOIUrl":"10.1186/s13550-025-01272-0","url":null,"abstract":"<p><strong>Background: </strong>^99mTc-labelled Dimercaptosuccinic acid ([^99mTc]DMSA) is a radiopharmaceutical commonly used to evaluate renal perfusion, structure, and morphology. However, the renal handling of [^99mTc]DMSA in humans remains unclear. Studies in humans with renal tubular dysfunction and animal experiments suggest that renal uptake of [^99mTc]DMSA occurs by glomerular filtration and subsequent proximal tubule reabsorption. The main aim of this study was to examine renal handling of [^99mTc]DMSA and the pathophysiological implications of [^99mTc]DMSA-based imaging in patients with chronic kidney disease (CKD) compared to healthy controls (HC).</p><p><strong>Results: </strong>Urinary excretion of [^99mTc]DMSA was 1.5-fold higher and more variable in CKD patients compared to HC. While [^99mTc]DMSA plasma clearance was only 1.1-fold higher in HC, the [^99mTc]DMSA uptake in the kidneys was 2.6-fold higher in HC compared to CKD patients and correlated inversely with the 24-hour urine excretion of [^99mTc]DMSA independent of GFR.</p><p><strong>Conclusion: </strong>Kidney [^99mTc]DMSA accumulation is consistent with tubular uptake following glomerular filtration. The relative DMSA uptake is lower in CKD patients, pointing to defective proximal tubular function in this patient group. Furthermore, the results suggest that [^99mTc]DMSA uptake could serve as a marker for tubule-interstitial function.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"75"},"PeriodicalIF":3.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced splenic uptake of [⁶⁸Ga]Ga-Pentixafor following first-line chemotherapy is associated with poor prognosis in patients with newly diagnosed multiple myeloma.","authors":"Qingqing Pan, Zhenying Chen, Silu Liu, Hongzhe Zhang, Jie Feng, Weibing Miao, Fang Li, Xinxin Cao, Yaping Luo","doi":"10.1186/s13550-025-01262-2","DOIUrl":"10.1186/s13550-025-01262-2","url":null,"abstract":"<p><strong>Background: </strong>We aim to investigate the prognostic value of [⁶⁸Ga]Ga-Pentixafor PET/CT in multiple myeloma (MM) patients.</p><p><strong>Results: </strong>This is a retrospective analysis of a prospective cohort study. Twenty-five patients with treatment-naïve, newly diagnosed MM were included. All participants underwent [⁶⁸Ga]Ga-Pentixafor PET/CT scans at baseline and after first-line chemotherapy. The endpoints included the time to progression (TTP) and the time to next treatment (TTNT). The correlation between PET/CT characteristics and survival was then analyzed. Patients with a decline in SUVmax of bone marrow of less than 40% from baseline demonstrated significantly shorter TTP and TTNT (estimated median TTP, 27.5 months [95% CI, 16.7-38.2] vs. not reached, P = 0.047; estimated median TTNT, 31.8 months [95% CI, 20.8-42.8] vs. not reached, P = 0.012). Patients with visually reduced splenic uptake in the follow-up [⁶⁸Ga]Ga-Pentixafor PET/CT from baseline exhibited significantly shorter TTP and TTNT (estimated median TTP, 24.4 months [95% CI, 7.9-24.4] vs. not reached, P = 0.018; estimated median TTNT, 31.9 months [95% CI, 18.5-31.9] vs. not reached, P = 0.043). A 20% reduction in splenic SUVmax was identified as a predictive indicator for shorter TTP and TTNT (estimated median TTP, 24.4 months [95% CI, 14.5-24.4] vs. not reached, P = 0.025; estimated mean TTNT, 31.9 months [95% CI, 18.5-31.9] vs. not reached, P = 0.048). Patients with splenic SUVmax < 5.0 at follow-up also exhibited significantly shorter TTP and TTNT. However, the splenic SUVmax at baseline PET/CT was not predictive of TTP or TTNT (P > 0.05).</p><p><strong>Conclusion: </strong>Reduced splenic uptake of [⁶⁸Ga]Ga-Pentixafor following first-line chemotherapy was predictive for poor prognosis in patients with newly diagnosed MM, while baseline splenic uptake is not associated with prognosis.</p><p><strong>Trial registration: </strong>ClinicalTrials. NCT03436342 Registered 25 October 2017, https://register.</p><p><strong>Clinicaltrials: </strong>gov/prs/app/action/SelectProtocol?sid=S0007IL2&selectaction=Edit&uid=U0001JRW&ts=6&cx=-3sdpwu .</p><p><strong>Clinicaltrials: </strong>NCT04504526 Registered 6 August 2020, https://clinicaltrials.gov/study/NCT04504526?cond=NCT04504526&rank=1 .</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"74"},"PeriodicalIF":3.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of patient hydration and forced diuresis on [¹⁸F]PSMA-1007 urinary bladder uptake in PET/CT imaging.","authors":"Aleksandr Igorevich Khalimon, Anastasia Igorevna Nikiforuk, Malika Maratovna Khodzhibekova, Gulnara Faridovna Khamadeeva, Daria Yurevna Khodakova, Tatyana Nikolaevna Lazutina, Irina Valentinovna Pylova, Aleksey Victorovich Leontyev, Vitaly Sergeevich Bobrov, Olga Valentinovna Mukhortova, Irakly Pavlovich Aslanidi","doi":"10.1186/s13550-025-01271-1","DOIUrl":"10.1186/s13550-025-01271-1","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"73"},"PeriodicalIF":3.1,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of in vivo binding kinetics and non-displaceable binding of [¹⁸F]SynvesT-1 in the rat brain.","authors":"Catriona Wimberley, Carlos J Alcaide-Corral, Timaeus E F Morgan, Mark G Macaskill, Bernadette Andrews, Holly McErlain, Valeria K Burianova, Andrew Sutherland, Adriana A S Tavares","doi":"10.1186/s13550-025-01270-2","DOIUrl":"10.1186/s13550-025-01270-2","url":null,"abstract":"<p><strong>Background: </strong>The synaptic vesicle glycoprotein 2 A (SV2A) has been identified as a biomarker of interest for neurological pathology. The SV2A specific radiotracer [¹⁸F]SynVesT-1 has shown good binding characteristics in mouse and human. The aim of this study was to characterize the binding parameters of [¹⁸F]SynVesT-1 in the rat brain and investigate simplified quantification methods. Twenty-one Positron Emission Tomography (PET) scans were conducted in male Sprague-Dawley rats with a bolus injection of [¹⁸F]SynVesT-1. Varying concentrations of non-radioactive SynVesT-1 were injected in an increasing mass dose paradigm (n = 21 ) with radioactivity in arterial blood recorded throughout. The radiometabolism was characterized in a further group (n = 7). The total volume of distribution (V_T) was estimated using compartmental modelling and Logan plot and then compared to the standardized uptake value at 30-60 min (SUV_30 - 60). Occupancy plots and a Lassen plot were generated.</p><p><strong>Results: </strong>The pharmacokinetics of [¹⁸F]SynVesT-1 PET showed rapid brain uptake and increasing doses of SynVesT-1 revealed a robust reduction in radiotracer uptake over all brain regions. The two-tissue compartmental model was most appropriate and the estimated V_T was highly correlated with Logan V_T, as was the SUV_30 - 60. The V_ND was estimated to be 3.75, which is 12.5% (pons) to 22% (thalamus) of the V_T. The estimated upper mass limit required to achieve 5% target occupancy is 0.48 µg/kg.</p><p><strong>Conclusion: </strong>[¹⁸F]SynVesT-1 shows good characteristics for imaging the rat brain, however care must be taken to achieve adequate molar activity to avoid mass dose affects (< 5% occupancy). Data showed no suitable reference region for [¹⁸F]SynVesT-1, however SUV_30 - 60 does give an appropriate surrogate for V_T.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"72"},"PeriodicalIF":3.1,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Test-retest properties of [¹¹C]PXT012253 as a positron emission tomography (PET) radiotracer in healthy human brain: PET imaging of mGlu4.","authors":"Per Stenkrona, Ryosuke Arakawa, Jiamei Guo, Benny Bang-Andersen, Sangram Nag, Mohammad Mahdi Moein, Zhisheng Jia, Zsolt Cselenyi, Christer Halldin, Andrea Varrone","doi":"10.1186/s13550-025-01266-y","DOIUrl":"10.1186/s13550-025-01266-y","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"71"},"PeriodicalIF":3.1,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12167413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interobserver variability in the preoperative assessment of future liver remnant function using hepatobiliary scintigraphy.","authors":"Kirsten de Vries, Jelmer E Oor, Suomi M G Fouraschen, Marieke T de Boer, Maarten W Nijkamp, Erik Groot Jebbink, Gilles N Stormezand, Simeon J S Ruiter","doi":"10.1186/s13550-025-01261-3","DOIUrl":"10.1186/s13550-025-01261-3","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"68"},"PeriodicalIF":3.1,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Call for candidates: Editor-in-Chief for EJNMMI Research.","authors":"","doi":"10.1186/s13550-025-01263-1","DOIUrl":"10.1186/s13550-025-01263-1","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"69"},"PeriodicalIF":3.1,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}